Five Prime Therapeutics Announces Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Five Prime Therapeutics (FPRX) Misses Q3 EPS by 22c
November 6, 2018 4:57 PM ESTFive Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($1.37), $0.22 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $5.77 million versus the consensus estimate of $7.4 million.
Cash Guidance:
Five Prime expects full-year 2018 net cash used in... More
